Page 1 of 8, showing 50 records out of 362 total, starting on record 1, ending on 50
| Publication |
Category |
Year |
|
362. Labrie, F. (2010) Hormonal therapy of prostate cancer. In: Martini L, Chrousos GP, Labrie F, Pacak K, Pfaff De, eds. Pathological Situations and Diseases, Progress in Brain Research. Elsevier. Chapter 14, Vol. 182 321-341. |
Prostate Cancer |
2010 |
|
361. Akaza, H., Labrie, F., Namiki, M. (2007) [A way of thinking of a MAB therapy for local/locally advanced prostate cancer: the theory and recent evaluation]. Gan To Kagaku Ryoho. Jpn J Cancer Chemotherapy, 34: 657-669. |
Prostate Cancer |
2007 |
|
360. Azzi, A., Rehse, P.H., Zhu, D.-W., Campbell, R.L., Labrie, F., Lin, S.-X. (1996) Crystal structure of human estrogenic 17beta-hydroxysteroid dehydrogenase complexed with 17beta-estradiol. Nat. Struct. Biol., 3: 665-668. |
Prostate Cancer |
1996 |
|
359. Bélanger, A., Candas, B., Dupont, A., Cusan, L., Diamond, P., Gomez, J.L., Labrie, F. (1994) Changes in serum concentration of conjugated and unconjugated steroids in 40- to 80-year old men. J. Clin. Endocrinol. Metab., 79: 1086-1090. |
Prostate Cancer |
1994 |
|
358. Bélanger, A., Rong, P.M., Liu, S., Lavoie, L., Labrie, F. (1993) Characterization and measurement of prostate-specific antigen using monoclonal antibodies. Clin. Invest. Med., 16: 409-415. |
Prostate Cancer |
1993 |
|
357. Bélanger, A., Van Halbeek, H., Graves, H.C.B., Grandbois, K., Stamey, T.A., Lihua, H., Poppe, I., Labrie, F. (1995) Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate, 27: 187-197. |
Prostate Cancer |
1995 |
|
356. Boivin, R.P., Poirier, D., Labrie, F. (1999) 17alpha-alkan (or alkyn) amide derivatives of estradiol as inhibitors of steroid-sulfatase activity. Steroids, 64: 825-833. |
Prostate Cancer |
1999 |
|
355. Candas, B., Cusan, L., Gomez, J.-L., Diamond, P., Suburu, R.E., Lévesque, J., Brousseau, G., Bélanger, A., Labrie, F. (2000) Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate, 45: 19-35. |
Prostate Cancer |
2000 |
|
354. Candas, B., Labrie, F., Gomez, J.L., Cusan, L., Chevrette, E., Levesque, J., Brousseau, G. (2006) Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits. J Urol, 175: 510-517. |
Prostate Cancer |
2006 |
|
353. Cantin, L., Faucher, F., Couture, J.F., de Jésus, K.P., Legrand, P., Ciobanu, L., Fréchette, Y., Labrecque, R., Singh, S.M., Labrie, F., Breton, R. (2007) Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally-designed steroidal ligand bearing a bulky chain directed toward helix 12. J Biol Chem, 282: 30910-9. |
Prostate Cancer |
2007 |
|
352. Chen, C., Li, X., Singh, S.M., Bélanger, A., Labrie, F. (1996) Additive in vivo growth-inhibitory effects of Flutamide and Finasteride on androgen-sensitive Shionogi 115 carcinoma. Endocrine-Related Cancer, 3: 217-227. |
Prostate Cancer |
1996 |
|
351. Chen, C., Poulin, R., Labrie, F. (1996) Large Shionogi tumors lose their responsiveness to Flutamide treatment. J. Steroid Biochem. Mol. Biol., 58: 489-494. |
Prostate Cancer |
1996 |
|
350. Chen, C., Puy, L.A., Simard, J., Li, X., Singh, S.M., Labrie, F. (1995) Local and systemic reduction by topical Finasteride or Flutamide on hamster flank organ size and enzyme activity. J. Invest. Dermatol., 105: 678-682. |
Prostate Cancer |
1995 |
|
349. Crawford, E.D., Miller, G., Labrie, F., Hirano, D., Batuello, J., Globe, M. (2001) Prostate cancer pathology, screening and epidemiology. Reviews in Urology, 3: S2-S10. |
Prostate Cancer |
2001 |
|
348. Cusan, L., Gomez, J.L., Diamond, P., Candas, B., Labrie, F. (1996) Combined androgen blockade with GnRH analogues and Flutamide at all stages of prostate cancer (Chapter 15), in: Filicori, M. et Flamigni, C., eds: Treatment with GnRH Analogs: Controversies and Prospectives, New-York, The Parthenon Publishing Group, pp 125-137. |
Prostate Cancer |
1996 |
|
347. Cusan, L., Gomez, J.L., Dupont, A., Diamond, P., Lemay, M., Moore, S., Labrie, F. (1994) Metastatic prostate cancer pulmonary nodules: beneficial effects of combination therapy and subsequent withdrawal of flutamide. Prostate, 24: 257-261. |
Prostate Cancer |
1994 |
|
346. Dufort, I., Soucy, P., Labrie, F., Luu-The, V. (1996) Molecular cloning of human type 3 3alpha-hydroxysteroid dehydrogenase that differs from 20alpha-hydroxysteroid dehydrogenase by seven amino acids. Biochem. Biophys. Res. Commun., 228: 474-479. |
Prostate Cancer |
1996 |
|
345. Dupont, A., Cusan, L., Gomez, J.L., Koutsilieris, M., Suburu, R., Emond, J., Labrie, F. (1993) Combination therapy with Flutamide and the LHRH agonist [D-Trp6-des-Gly-NH2]LHRH ethylamide in stage C prostatic carcinoma. Br. J. Urol., 72: 629-634. |
Prostate Cancer |
1993 |
|
344. Dupont, A., Gomez, J.L., Cusan, L., Koutsilieris, M., Labrie, F. (1993) Response to Flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol., 150: 908-913. |
Prostate Cancer |
1993 |
|
343. El-Alfy, M., Luu-The, V., Huang, X.F., Berger, L., Labrie, F., Pelletier, G. (1999) Localization of type 5 17β-hydroxysteroid dehydrogenase, 3β-hydroxysteroid dehydrogenase and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology, 140: 1481-1491. |
Prostate Cancer |
1999 |
|
342. El-Alfy, M., Pelletier, G. Hermo, L.S., Labrie, F. (2000) Unique features of the basal cells of human prostate epithelium. Microsc. Res. Tech., 51: 436-446. |
Prostate Cancer |
2000 |
|
341. Gomella, L.G., Labrie, F., Gamito, E.J., Brawer, M.K. (2001) Prostate cancer: risk assessment and diagnostic approaches. Reviews in Urology, 3: S31-S38. |
Prostate Cancer |
2001 |
|
340. Gomez, J.L., Dupont, A., Cusan, L., Tremblay, M., Suburu, E.R., Lemay, M., Labrie, F. (1992) Incidence of liver toxicity associated with the use of Flutamide in prostate cancer patients. Am. J. Med., 92: 465-470. |
Prostate Cancer |
1992 |
|
339. Gomez, J.L., Dupont, A., Cusan, L., Tremblay, M., Tremblay, M., Labrie, F. (1992) Simultaneous liver and lung toxicity related to the non-steroidal antiandrogen Nilutamide (Anandron): a case report. Am. J. Med., 92: 563-566. |
Prostate Cancer |
1992 |
|
338. Kelloff, G.J., Lieberman, R., Brawer, M.K., Crawford, E.D., Labrie, F., Miller, G.J. (1999) Strategies for chemoprevention of prostate cancer. Prostate Cancer and Prostatic Diseases, 2: 27-33. |
Prostate Cancer |
1999 |
|
337. Koutsilieris, M., Dupont, A., Gomez, J.L., Cusan, L., Suburu, R., Diamond, P., Labrie, F. (1994) Stratification of stage D2 prostate cancer patients by a disease aggressiveness score and its use in evaluating disease response and outcome to combination hormonal therapy (GnRH-A plus Flutamide). Anticancer Res., 14: 627-634. |
Prostate Cancer |
1994 |
|
336. Lévesque, M.H., El-Alfy, M., Cusan, L., Labrie, F. (2009) Androgen receptor as a potential sign of prostate cancer metastasis, The Prostate, 69: 1704-1711. |
Prostate Cancer |
2009 |
|
335. Labrie, C., Flamand, M., Bélanger, A., Labrie, F. (1996) High bioavailability of DHEA administered percutaneously in the rat. J. Endocrinol., 150: S107-S118. |
Prostate Cancer |
1996 |
|
334. Labrie, F. (1992) Stratégie efficace et peu coûteuse pour la détection du cancer de la prostate à un stade précoce alors que la guérison est possible. Médecine/Sciences, 8: 703-706. |
Prostate Cancer |
1992 |
|
333. Labrie, F. (1993) GNRH agonists in prostate cancer, in GnRH analogues - The State of the Art 1993, New York, Parthenon Publishing, pp 103-121. |
Prostate Cancer |
1993 |
|
332. Labrie, F. (1993) Intracrinology: its impact on prostate cancer. Curr. Opin. Urol., 3: 381-387. |
Prostate Cancer |
1993 |
|
331. Labrie, F. (1993) Mechanism of action and pure antiandrogenic properties of Flutamide. Cancer, 72: 3816-3827. |
Prostate Cancer |
1993 |
|
330. Labrie, F. (1993) Non-steroidal antiandrogens, in: Droz, J.P., Cvitkovic, E., Armand, J.P. et Khoury, S., eds: Handook of Chemotherapy in Clinical Oncology, London, Scientific Communication International Ltd., pp 389-391. |
Prostate Cancer |
1993 |
|
329. Labrie, F. (1993) Present status of endocrine therapy of prostate cancer. Eur. Urol. Today, 3: 10-11. |
Prostate Cancer |
1993 |
|
328. Labrie, F. (1994) Intracrinology and Cancer Therapy. Science Watch, 5: 3-4. |
Prostate Cancer |
1994 |
|
327. Labrie, F. (1994) Les antiandrogènes dans le cancer de la prostate. La Lettre du Pharmacologue, 8: 190-195. |
Prostate Cancer |
1994 |
|
326. Labrie, F. (1994) Prostate cancer [Letter to the Editor: Reply to 342: 901-5, 1993]. Lancet, 343: 491. |
Prostate Cancer |
1994 |
|
325. Labrie, F. (1994) Prostate cancer [Letter to the Editor: Reply to Cheney re 343: 491-2, 1994]. Lancet, 343: 976-977. |
Prostate Cancer |
1994 |
|
324. Labrie, F. (1995) Endocrine therapy of prostate cancer: optimal form and timing. J. Clin. Endocrinol. Metab., 80: 1066-1071. |
Prostate Cancer |
1995 |
|
323. Labrie, F. (1997) Flutamide plus castration in patients with previously untreated prostate cancer [Letter to the Editor re: Noldus et al. 47: 713-8, 1996]. Urology, 50: 479. |
Prostate Cancer |
1997 |
|
322. Labrie, F. (2000) Prostate cancer and combined androgen blockade at all stages of disease, in: Khayat, D. et Hortobagyi, G.N., eds: Progress in Anti-Cancer Chemotherapy, France, Springer, pp 171-187. |
Prostate Cancer |
2000 |
|
321. Labrie, F. (2000) Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support. Prostate, 43: 214-222. |
Prostate Cancer |
2000 |
|
320. Labrie, F. (2000) Screening and hormonal therapy of localized prostate cancer show major benefits on survival. Cancer J. Sci. Am., 6: S182-S187. |
Prostate Cancer |
2000 |
|
319. Labrie, F. (2001) Le cancer de la prostate: blocage combiné des androgènes comme traitement à tous les stades de la maladie. Oncologie, 3: 3-12. |
Prostate Cancer |
2001 |
|
318. Labrie, F. (2002) Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease. Mol Cell Endocrinol, 198: 77-87. |
Prostate Cancer |
2002 |
|
317. Labrie, F. (2002) Endocrine-sensitive cancers of the prostate and breast, in: Baster, J., Melmed, S. et New, M., eds: Genetics in Endocrinology, Lippincott-William and Wilkins, pp 607-661. |
Prostate Cancer |
2002 |
|
316. Labrie, F. (2003) Hormonal therapy in the management of prostate cancer at all stages of the disease, in: Syrigos, K.N., ed. Prostate Cancer: Biology, Diagnosis and Management, London, UK, Oxford University Press, pp 301-314. |
Prostate Cancer |
2003 |
|
315. Labrie, F. (2004) Current status of endocrine therapy in localized prostate cancer: cure has become a strong possibility. Brazilian J Urol, 30: 3-12. |
Prostate Cancer |
2004 |
|
314. Labrie, F. (2004) Major role of androgen blockade in the success of prostate cancer treatment: cure has become a very good possibility. Prostate Cancer Communication Newsletter, 20: 3-11. |
Prostate Cancer |
2004 |
|
313. Labrie, F. (2004) Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer. J Androl, 25: 305-313. |
Prostate Cancer |
2004 |